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ABSTRACT
Stem cells and their derivatives hold great promise to advance regenerative medicine. Critical to the
progressionof this field is the identificationandutilizationof antibody-accessible cell-surfaceproteins
for immunophenotyping and cell sorting—techniques essential for assessment and isolation of de-
fined cell populations with known functional and therapeutic properties. Beyond their utility for cell
identification and selection, cell-surface proteins are alsomajor targets for pharmacological interven-
tion. Although comprehensive cell-surface protein maps are highly valuable, they have been difficult
to define until recently. In this review, we discuss the application of a contemporary targeted
chemoproteomic-based technique for defining the cell-surface proteomes of stem and progenitor
cells. In applying this approach to pluripotent stem cells (PSCs), these studies have improved the bi-
ological understanding of these cells, led to the enhanced use anddevelopment of antibodies suitable
for immunophenotypingand sorting, andcontributed to the repurposingof existing drugswithout the
need for high-throughput screening. The utility of this latter approach was first demonstrated with
human PSCs (hPSCs) through the identification of small molecules that are selectively toxic to hPSCs
and have the potential for eliminating confounding and tumorigenic cells in hPSC-derived progeny
destined for research and transplantation. Overall, the cutting-edge technologies reviewed here will
accelerate the development of novel cell-surface protein targets for immunophenotyping, new re-
agents to improve the isolation of therapeutically qualified cells, and pharmacological studies to ad-
vance the treatment of intractable diseases amenable to cell-replacement therapies. STEM CELLS
TRANSLATIONAL MEDICINE 2016;5:1–8
SIGNIFICANCE
Chemoproteomic techniques that target the cell surfaceome have begun to improve cell immuno-
phenotyping, advance antibody development and usage for sorting, and identify drug targets that
advance pharmacological screening and drug repurposing. The development of these techniques
and application to stemcells has the potential to accelerate efforts toward the safe use of pluripotent
stem cell-derived progeny in regenerative medicine without complicating tumorigenic potential.
INTRODUCTION
Human stemcells and their progeny are central to
the advancement of regenerative medicine and
cell-based therapies of intractable syndromes like
Parkinson’s disease, heart failure, diabetes, and
spinal-cord injuries. The regenerative capacity
of these cells relies on their ability to self-renew
and to differentiate into one or more cell types.
In the clinic, their application to regenerative
medicine can be credited, at least partially, to
the use of immunophenotyping and cell-sorting
techniques that target mainly surface-accessible
plasma membrane proteins. These techniques
permit the identification, separation, and isola-
tion of cells according to defined properties. In
the case of the prototypic hematopoietic system,
only long-term repopulating hematopoietic stem
cells (HSCs), characterized by CD34+, CD90+,
CD382, and Lin2 surface proteins [1], can fully re-
constitute the hematopoietic system for success-
ful treatment of some blood disorders, cancers,
and autoimmune diseases [2, 3]. Similarly, mes-
enchymal stem cells/multipotent stromal cells
(MSCs) have been extensively investigated to de-
termine their efficacy in treating heart disease,
neurodegenerative disorders, bone and cartilage
defects, and other syndromes [4]. Although the
immunomodulatory and paracrine effects of
MSCs appear promising, surface markers for
immunophenotyping and sorting of MSCs are of-
ten insufficient, because processed lipoaspirate
and stromal vascular fractions of adipose tissues
represent highly heterogeneous cell populations
that include inflammatory, endothelial , and he-
matopoietic cells, several of which are positive
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forMSC selectionmarkers such as CD34 [5]. Importantly, thema-
jority of stem or progenitor cells destined for regenerative med-
icine have not yet been adequately immunophenotyped for
robust isolation of homogeneous cell populations suitable for
clinical applications. The application of sorted stem cells and their
progeny to treatmany intractable syndromes, therefore, remains
in its infancy.
One of the best cell sources for regenerativemedicinemay be
embryonic stem cells (ESCs) or induced pluripotent stem cells
(iPSCs).Humanpluripotent stemcells (hPSCs) have the advantage
in vitro of being able to differentiate into almost any cell type and
can serve as anunlimited cell source for treatingdegenerative dis-
eases or syndromes. Human iPSCs have overcome many of the
ethical limitations associatedwithhumanESCs (hESCs), but signif-
icant hurdles remain that preclude broad application in the clinic.
Most differentiating cultures of hPSCs are heterogeneous and
contain multiple cell type(s) or similar types of cells at different
developmental stage(s). Moreover, these cultures may contain
contaminating undifferentiated hPSCs that are tumorigenic. Cell
purification techniques and elimination of tumorigenic potential
usually require genetic manipulation or the use ofmetabolic sub-
strates that may affect function [6]. Although cell-sorting tech-
niques exist that are based on the presence of epitopes that
enable reproducible, nonmutagenic, and high-throughput isola-
tion and assessments of HSC lineages [1, 3], isolation of immuno-
phenotypedhPSCprogeny that ensureboth cell-typehomogeneity
and stage specificity has been underutilized.
Despite their critical importance to biology, disease, pharma-
cological targeting, immunophenotyping, and sorting, cell-
surface proteins have been historically understudied because
of technical limitations and antibody availability. Chemoproteo-
mic techniques that target the cell surfaceome have begun to
overcome these limitations by providing comprehensive analyses
of surface-accessible protein domains. Although the vast number
andvaried typesofproteomicapproachesare virtually unlimited—
and undoubtedly informative—we will emphasize the utility of
the cell surface capture (CSC) technology to generate experimen-
tal evidence that confirms protein identity, localization to the cell
surface, transmembrane orientation, andN-glycosite occupancy.
Identification of N-glycoproteins on stem cells and their deriva-
tives has already begun to improve cell immunophenotyping, ad-
vance antibody development and usage for sorting, and identify
drug targets that advance pharmacological screening and drug
repurposing.
MAMMALIAN CELL SURFACE AND
TECHNOLOGICAL ADVANCEMENTS
Mammalian membrane proteins are structurally diverse, partici-
pate in a wide variety of biological processes, and comprise al-
most 22% of all proteins encoded by the genome. Among the
membrane proteins identified in the genome, ∼38% have been
associatedwith a disease [7]. Some of these proteins are involved
with cell-to-cell communication, whereas others form channels
or pores to allow molecules to cross the membrane. Membrane
proteins are also useful drug targets, because almost 60% of the
pharmacological agents approved by the Food and Drug Admin-
istration target membrane proteins [7–9].
A subset of membrane proteins is located on the plasma
membrane or cell surface. The vast majority (∼90%) of surface
proteins have oligosaccharide (glycan) chains covalently attached
either to an oxygen molecule present in an amino acid (O-linked)
or to an asparagine residue present on polypeptide side chains
(N-linked). Together with lipids, these glycoproteins form a bar-
rier between the intracellular and extracellular compartments.
Someof theseproteins areexclusively localized to thecell surface,
whereas others shuttle among the cell surface and intracellular
compartments [10]. Functionally, plasma membrane proteins
participate in intercellular and intracellular communication, cel-
lular structure, adhesion, transport, and act as environmental
sensors.
Direct identification and assessment of surface proteins
(i.e., the surfaceome) by using proteomic approaches have tradi-
tionally been challenging because of the relatively low abun-
dance, hydrophobicity, and difficulty of purifying plasma
membrane proteins away from intracellular membranes by bio-
physicalmethods. Innovative approaches have been used to eval-
uate the surfaceome based on transcriptomics [11], antibody
screening, and physical and affinity enrichment strategies cou-
pled with proteomics [12], although each has limitations. Tran-
script abundance does not always correlate with protein
abundance on the cell surface, and transcriptomic data fail to in-
form subcellular localization. Although significant efforts are un-
derway to manually curate proteomics repositories (e.g.,
UniProt), the precise location of many membrane proteins are
as-yet unannotated, which is further confounded by the fact that
membrane proteins can be sequestered within the cell and only
cycled to the cell surface in response to developmental events or
cell signaling (e.g., aquaporins in kidney) [13]. The orientation in
which transmembrane proteins lie within the lipid bilayer is crit-
ical to the future development of new affinity reagents that rec-
ognize extracellular epitopes on live cells. For this reason,
continued efforts to experimentally determine transmembrane
protein orientation are needed, because predictions can be incor-
rect [14, 15]. Although antibody-based approaches, such as im-
munofluorescence imaging and flow cytometry, offer the
ability tomonitor protein abundance and can inform localization,
they require validated and specific antibodies that are often not
available for cell-surface proteins. Moreover, determining opti-
mal experimental conditions for each cell type of interest and val-
idating antibody specificity requires significant timeandeffort. As
with all antibody-based methods, even if highly specific anti-
bodies are available, they require the epitope to be accessible,
which may not be predictable among cell types because unex-
pected conformational changes and posttranslational modifica-
tions can mask epitope availability.
In contrast to the challenges faced with transcriptomic and
antibody-based approaches, the development of the chemopro-
teomic CSC technology has specifically enabled the discovery-
driven analysis of the cell surfaceome for a wide variety of cell
types. The approach pioneered by Wollscheid et al. [16] takes
advantage of the prediction that .90% of cell surface proteins
are glycosylated [17, 18]. Experimentally, extracellular oligosac-
charides are oxidized and biotinylated by using membrane-
impermeable reagents (Fig. 1). Proteins are enzymatically
digested, and the resulting biotinylated glycopeptides are
enriched by using streptavidin beads. Through the actions of
the enzyme peptide-N-glycosidase F (PNGaseF), which cleaves
between the innermostN-acetylglucosamine and asparagine res-
idues, deglycosylated peptides are released and analyzed by high
mass accuracy mass spectrometry (MS). During the data analysis
process, cell surface proteins are confidently identified by the
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Figure 1. Overview of the CSC-technology workflow and resulting data. (A): The experimental workflow begins with biotinylation of extracel-
lular glycans on living cells. Subsequently, cells are lysed, proteins are enzymatically digested, and biotinylated glycopeptides are captured by
using immobilized streptavidin. After extensive washing to remove nonspecific binders, N-glycans were specifically cleaved from their peptide
backbone via PNGaseF,which liberated the formerlyN-glycosylated peptides containing a deamidated asparagine. (B): Transmembrane protein
topology is confirmed by CSC-technology data, thereby facilitating the development of antibodies recognizing extracellular epitopes available
on live cells. Transmembrane protein topology graphs are provided for 5-hydroxytryptamine receptor 2C and g-aminobutyric acid receptor
subunita-3 identified in human pluripotent stem cells via the CSC-technology. Abbreviations: CSC-Technology, cell surface capture technology;
GABRA3, g-aminobutyric acid receptor subunit a-3; HTR2C, 5-hydroxytryptamine receptor 2C; PNGaseF, peptide-N-glycosidase F.
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signaturedeamidation (+0.984Da)observedontheasparagineres-
idue within the conserved N-glycosylation sequence motif (Asn-x-
Ser/Thr/Cys [NxS/T/C];wherex is anyaminoacidexceptproline). In
this strategy, the experimental output confirms the occupancy of
individual N-glycosylation sites of identified proteins and thereby
confirms extracellular domains. Complementary variations of this
approach that rely on cysteine- or lysine-containing peptides have
alsobeendescribed [19], andquantitativeassessments using label-
free and label-based methods are beginning to be used [15, 20].
Although theCSC technologymethod importantly offers the ability
toviewahighly specific “snapshot”of thecell surfaceataparticular
time or stage—and thereby is advantageous over predictive ap-
proaches or those that rely on more generic membrane protein-
enrichment strategies—the extensive sample-handling steps
involved in the workflow ultimately result in the requirement for
large amounts of starting material (e.g., 30 million to 100 million
cells per experiment). Therefore, improvements that reduce the
numbers of starting cells required for this approach will be critical
for the future application of CSC technology to small cell popula-
tions (e.g., rare cell types or primary cells). With recent technolog-
ical improvements in labeling chemistry and automated sample
handling (R.L.G. and Bernd Wollscheid, unpublished data), the
numbers of cells required for a CSC technology experiment are
approaching 10 million to 20 million cells, and the scope is being
expanded to include proteins that are exclusively O-glycosylated,
whichareasmall,but significant, populationoverlookedby thecur-
rentmethod.Moreover, aswith anymass-spectrometry approach,
this approach does not permit live cell recovery, and it is not yet
applicable to very small numbers of cells, such as endogenous
stem/progenitor cells, unless they can be expanded in vitro.
ANALYSIS OF PSCS BY CSC TECHNOLOGIES
Wollscheid et al. were the first to report the cell surface N-glyco-
protein landscape of undifferentiated and differentiating mouse
ESCs (day 4, embryoid bodies; day 8, neural progenitor cells) [16].
They showed that leukemia inhibitor factor receptor abundance
decreased, whereas fibroblast-like growth factor (FGF) receptor
type 2 increased from days 0 to 8, thus illustrating that surface
protein transitions can be informative of differentiation time.
We subsequently demonstrated that cell sorting using candidate
markers identified via the CSC technology could isolate iPSCs
reprogrammed from mouse (m) fibroblasts. Costaining with
EpCam (CD326) and PECAM1 (CD31) proved better at isolating
putative iPSCs with elevated levels of Nanog, Oct4, Sal4, and
Rex1 transcripts than isolation with antibodies targeting SSEA1
alone or costaining of CD112 and CD31. CD31+ cells sorted with
CD326 were easily cultured, whereas those isolated with
CD112 were difficult to maintain long-term in culture and had
low levels of Nanog transcripts. We also found that surface
marker heterogeneitywas greater onmouse ESCs thanpreviously
reported [21]. Antibodies to EFNA2 and GPC3 had nonuniform
staining in mouse ESC (mESC) colonies, whereas GP130lo cells
plated more efficiently and were more tumorigenic than GP130hi
cells.Marker selection is therefore critical for isolation of authen-
tic iPSCs.
Although the CSC technology is highly specific, and tech-
niques like total spectral count normalization or stable isotopic
labeling by amino acids in cell culture facilitate relative quantifi-
cation [20, 22], the implementation of CSC technology into a
quantitative discovery workflow remains challenging and subject
to strict experimental design. With this technique, only formerly
N-glycosylated peptides are identified. In the event that a protein
has a singleN-glycosylation site, a singlepeptidewill be identified.
This poses challenges to obtaining robustMS-based quantitation,
which ideally relies on multiple peptides within a protein. Never-
theless, we have successfully performed quantitative compari-
sons between mESCs and mouse extraembryonic endoderm
cells using stable isotope labeling with amino acids in cell culture
(SILAC) [20]. In these experiments, SILAC ratios proved consistent
with flow-cytometry analyses and, when available, were consis-
tent with published reports. Going forward, it is likely that CSC
technology approaches will continue to serve an invaluable role
for the discovery of authentic surface-accessible proteins and
their initial semiquantitative assessment. Once proteins of inter-
est are identified, applying contemporary, targetedMS-based ap-
proaches forquantitationwith samplepreparation strategies that
are designed to enable more complete coverage of the protein
(i.e., not only the N-glycopeptide) will circumvent these limita-
tions. Targeted MS-based quantitation strategies that accurately
quantify hundreds of targets in a single experiment without anti-
bodies [23] will be critical to the further evaluation and candidate
refinement for newly discovered targets before expensive and
time-consuming antibody generation.
Ultimately, high-quality antibodies (e.g., recombinant) that
recognize extracellular epitopes on live cells are necessary to ad-
vance immunophenotyping and sorting of stem-cell subpopula-
tions analogous to the isolation of therapeutically relevant
CD34lo/- HSC populations [1]. For this reason, an added advantage
of the CSC technology approach is its ability to confirm or correct
predicted protein orientations [24]. Protein identity, transmem-
brane orientation, and glycosylation site occupancy are deter-
mined simultaneously in a CSC technology experiment. As
described above and as illustrated in Figure 1, highmass accuracy
MS can provide unambiguous identification of peptides contain-
ing a deamidated asparagine within the NxS/T/C motif, which re-
sults from the specific capture and release of N-glycopeptides
during the CSC technology workflow. When this information is
coupledwith scanning tools that permit the selection of antigenic
peptide sequences that avoid posttranslational modifications,
nonspecific sequences, transmembrane regions, and signal pep-
tides, the success inmaking antibodies suitable for cell sorting can
be enhanced and, because only extracellular domains will be
targeted, are more cost-effective than traditional methods
[25] (R.L.G., unpublished data).
CELL SURFACE PROTEIN ATLAS, IMMUNOPHENOTYPING,
AND BARCODES
Extracellular epitopes from hundreds of cell surface N-glycopro-
teins can be experimentally verified in a single CSC technology
experiment. When these data are analyzed comparatively, classi-
fication of a particular protein as routinely versus rarely observed
among cell types can bemade immediately, thus rapidly focusing
a candidate list fromhundreds to tens. To enable this type of anal-
ysis, CSC technology data from more than 80 mouse and human
primary cells and cell lines (normal and diseased) have now been
deposited into a publicly accessible repository, the Cell Surface
Protein Atlas (CSPA; http://wlab.ethz.ch/cspa) [15]. The informa-
tion has been highly informative to distinguish among germ layer
lineages (endoderm, mesoderm, and ectoderm). Moreover,
Wollscheid et al. have been at the forefront of efforts to identify
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Figure2. Utility ofCSC-technology todrug repurposing andbarcodedevelopment. Combining theCSC-technologywith theCell SurfaceProtein
Atlas provides a rapid method for identifying proteins that may be informative or useful for targeting a specific cell type. Proteins identified as
potentially informative canbepursued for drug repurposing or cell surfacemarker barcodedevelopment. In the case of drug repurposing, a new
tool “Targets-Search” should facilitate the identification of drugs for selected targets. For barcode development, hierarchical clustering can
benefit the selection ofmarker combinations thatmayprovemost useful. Publicly available transcriptomic data canbeused to further eliminate
proteins that are unlikely to be informative for a particular cell type. Subsequently, targetedmass spectrometry can quantify protein abundance
of selected targets among cell types and/or stages of differentiation to further refine putative markers before antibody selection or develop-
ment. Abbreviations: CSC-Technology, cell surface capture technology; FDA, Food and Drug Administration.
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markers on cancer cells that may be applicable to basic research
and patient diagnoses [26–29]. However, the application of the
CSC technology to cancer stem cells has been limited because
of the difficulty in isolating sufficient numbers of these stem cells
for labeling and processing.
With regard to blood and PSCs, the CSPA has proven instru-
mental in the identification of informative markers. CD29,
CD90, CD156c, and CD298, for example, are observed in almost
all cell types, whereas CD158 (types b2, f1, h, and i), CD159a,
and CD161 are only observed in natural killer cells [15]. Compar-
isonsbetweenhumanandmousePSCs showthatNRP1,COLEC12,
and CD13 are restricted to mPSCs. Atlas comparisons further
identified 48 markers that were unique or highly prevalent in
hPSCs relative to other cell types and amenable to cell sorting
(e.g., EPCAM [CD326], FGFR3 [CD333], EFNA3, and CDH3) [30].
It also permitted the identification of 15 proteins that were not
observed on hPSCs, but were present in human fibroblasts. Flow
cytometry-based analyses were consistent with CSC technology
data, leading to the classification of these proteins as negative se-
lectionmarkers (e.g., CD26, CD304, and COLEC12)within the con-
text of distinguishing hPSCs from their fibroblast precursors. As
these examples illustrate, the output from CSPA-based analyses
can be utilized as a basis for generating “barcodes” that confer
cell-type identify (Fig. 2) [12]. Such an approach is applicable
not only to hPSCs, but to anymammalian cell type analyzed in this
manner, including any type of stem/progenitor cells or their prog-
eny. Importantly, because proteins unique to a single cell type are
rare, it is expected that panels of surface markers will be neces-
sary for adequate barcoding and sorting of well-defined stem cell
populations [15, 30].
Finally, the CSPA quantitative expression matrix permits cat-
egorization of proteins based on relative quantitative levels. This
represents an efficient filtering mechanism for the identification
of candidate proteins for subsequent functional studies or for
evaluating surfacemarkers identified through sorting techniques
alone. CD172a (SIRPA), for example, has been described as useful
for hPSC-derived cardiomyocyte (CM) selection, but not for
mPSC-CMs [31]. From CSC analyses of mouse and human cells,
we observed that this protein is, in fact, present on both human
and mouse PSC-CMs. We confirmed that CD172a could be de-
tected on mPSC-CM by using an alternative antibody to the
one used in the original study, highlighting a common challenge
for antibody-based studies, wherein the absence of a positive sig-
nal does not confirm absence of the protein, but could indicate
that a conformational or posttranslational modification masks
the epitope required for antibody recognition. Moreover, in our
CSC technology analyses of mPSC, hPSC, and their cardiogenic de-
rivatives ([20,21,30]andunpublisheddata),wehave identifiedpre-
viously reported cell surface markers for stem cell-derived cardiac
progenitors and cardiomyocytes—including ROR2, KDR, VCAM1
(CD106), ALCAM (CD166), ANPEP (CD13), PDGFRa (CD140a), EMI-
LIN2, KIT (CD117), and CD172a—within a handful of experiments
without the use of antibodies. Comparisons of these data within
the published CSPA that have been augmented with unpublished
analyses of primary hepatocytes, human iPSC (hiPSC)-derived he-
patic progenitors, pigmented retinal epithelial cells, blood cells,
and cardiac fibroblasts quickly reveal that ROR2, VCAM1, ALCAM,
ANPEP, PDGFRa, and SIRPA are observed across many different
noncardiomyogenic cell types, which may impact their utility for
identification of a single or defined cell population. Although the
presence of a protein across disparate cell types may not preclude
its utility for a specific context in vitro, these observations empha-
size the need for extensive functional evaluations of cell popula-
tions that are identified and selected by cell surface markers.
DRUG REPURPOSING AND ELIMINATION OF TUMORIGENIC CELLS
Human PSCs or the presence of contaminating hPSCs in differenti-
ated progeny is positively correlated with tumorigenesis, which
represents a major hurdle to the use of hPSCs and their progeny
for regenerative medicine [32]. To rid differentiated hPSC progeny
of any residual tumorigenic cells, researchers haveused a variety of
approaches, including the use of suicide genes, lactate, SSEA-5, and
Claudin-6-based selection approaches [6, 33–36]. Although effec-
tive, each has limitations because of genetically intrusive gene de-
livery systems, manipulation of cells, or incomplete purity. These
drawbacks have led to the suggestion that pharmacological ap-
proaches thatmeetFoodandDrugAdministration (FDA)guidelines
are needed to eliminate tumorigenic potential from hPSC deriva-
tives destined for transplantation.
The development of high-throughput screening (HTS) plat-
forms has beenpivotal for drugdiscovery and for the development
of novel therapies [37]. The most fruitful targets of HTS platforms
have beenmembrane proteins. Currently, almost half of the drugs
that targetmembrane proteins are directed at rhodopsin-like class
I G-protein-coupled receptor superfamilymembers [38]. The over-
all success of HTS platforms in identifying drug targets has in large
part beenbecause of the availability of reliable cell-basedmonitor-
ing systems for downstream outputs like calcium signals, cAMP, or
cell death. The rate at which drugs are developed against new pro-
tein families, however, continues to be relatively slowbecause of a
lack of appropriate readouts, reagent universality, cost, and con-
founding background signals [39].
The first success story of CSC technology data leading to drug
repurposing came about through comparisons of hPSCs to other
cell typeswithin theCSPA [30]. In that study,we focusedon solute
carrier proteins, including members (GLUT1, 3, and 4) of the glu-
cose transporter superfamily. Although it is notpossible tomakea
direct correlationofproteinabundanceamongdifferentproteins,
the observation that GLUT1 was detected by significantly more
spectra (hundreds) than GLUT3 and GLUT4 (tens) suggested that
GLUT1may bemore abundant and the critical transporter for glu-
cose in hPSC. Because a number of inhibitors had been identified
thatwere reportedly “selective” forGLUT1 in cancer [40], this tar-
get protein was chosen for proof-of-principle experiments.
Two reported small-molecule inhibitors of GLUT1, including
STF-31 andWZB117, and glucose deprivation were tested for tox-
icity in hPSCs in direct comparison with PlurSIn1, which previously
hadbeen identified throughHTStechniquesbyBen-Davidetal. [41,
42]. In these experiments, glucose deprivation proved highly toxic
to subconfluent hPSCs, but toxicity was delayed and decreased in
confluent cultures of hPSCs [30, 42]. WZB117, an irreversible
GLUT1 inhibitor, andPluriSIn1werehighly toxic tohPSCsatsubcon-
fluency, but at high densities, these smallmolecules did not induce
significant cell death. WZB117 and PluriSIn1 weremore rapid than
STF-31 at inducing hPSC toxicity in low-density cultures, whereas
only STF-31 was effectively toxic to high-density hPSC cultures.
STF-31 treated cocultures of hPSC and human fibroblasts or hPSC
and hPSC-CM (seeded at varying density) selectively killed hPSCs,
and in teratoma assays (unpublished data), STF-31 (10 mM) treat-
ments of .24 hours are required to prevent tumor formation in
nonobese diabetic-severe combined immunodeficient mice,
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irrespective of plating density, whereas shorter treatments (e.g.,
18 hours) do not prevent the formation of teratomas. Although
inhibition of oleic acid biosynthesis, glucose deprivation, and
GLUT1 inhibition are toxic to hPSCs in low-density cultures, only
treatment with STF-31 showed toxicity at high cell density.
Although STF-31 was originally reported to be an inhibitor of
GLUT1, we determined that STF-31 mediates toxicity through in-
hibition of nicotinamide phosphoribosyltransferase, an enzyme
required for one of the NAD salvage pathways and biologically
critical for normal hPSC function (see [42] for details). These
results suggest that targeted proteomic analyses of cells grown
under a variety of culture conditions can be an important comple-
ment to HTS studies, especially considering the technical chal-
lenges related to controlling cell density and cellular responses
to stress in high-throughput culture formats (e.g., 96- and 384-
well plates). Altogether, these studies indicate that metabolic
strategies can be successfully used to prevent teratoma forma-
tion without genetic manipulation, cell sorting, and before cell
transplantation.
IDENTIFICATION OF CELL SURFACE TARGETS FOR ENHANCED
THERAPEUTIC APPLICATIONS
Application of CSC technology for specific identification of cell
surface proteins combined with CSPA comparisons [30, 42] en-
ables the selection of protein targets for drug repurposing with-
out costly HTS screening. To facilitate these types of analyses, we
have developed and are beginning to test a new web-based plat-
form called Targets-Search that directly links known drugs and
small molecules with surface proteins identified either experi-
mentally by CSC technology or predicted from transcriptomic
data (K.R.B. and Bin Yan, manuscript in preparation). This web-
based server collects published and otherwise publicly available
bioinformatics data for genes, proteins, and drugs, and is capable
of associating each of thesewith human diseases. This platform is
designed to serve as a comprehensive resource center for inte-
grated and systemic exploitation of multimolecule interactions
among drug targets, protein networks, human diseases, and can-
cer. As anexemplar,wehave reanalyzed thehPSCcell surfacepro-
teome and were able to identify 101 proteins that are targets of
FDA-approved drugs. We also identified another 55 proteins that
may be targeted by some of the 12,257 small molecules available
at the Therapeutic Targets Database (http://bidd.nus.edu.sg/
group/cjttd) and the European Molecular Biology Laboratory
ChEMBL database (http://www.ebi.ac.uk/chembldb). Included
among the identified targets are G-proteins, tyrosine protein ki-
nases, solute carrier family proteins, and transmembrane trans-
porters. Several of the identified drugs/small molecules
specifically target tyrosine protein kinases and ABCC4 trans-
porters [43] and are being tested to determine whether theymod-
ulate signaling processes in hPSCs and their derivatives, and
whether these kinases/transporters represent viable therapeutic
targets. If these drugs lead to altered metabolism and differentia-
tion,weexpect that this integrated resourcewill becomplementary
to existing HTS technologies and that the output will facilitate drug
repurposing efforts and enhance our biological understanding of
stem cells and their differentiation in vitro (Fig. 2).
CONCLUSION
Contemporarymass spectrometry-based proteomicmethods are
poised to make a rapid and significant impact on the use of stem
cells and their derivatives for regenerative medicine. In this re-
view, we have emphasized the utility of the CSC technology for
the generation of experimental evidence that confirms protein
identity, localization to the cell surface, transmembrane orienta-
tion, andN-glycosite occupancy, and how these results can foster
antibody development and drug repurposing. Although we have
focused on an analysis of human and mouse pluripotent cells, the
strategies described here are universally applicable to any stem cell,
progenitorcell,or theirderivatives.Analogousto thedevelopmentof
immunophenotyping and sorting techniques for HSCs, the merging
of broad-based stem cell analyses with the CSC technology, CSPA,
and a new bioinformatics platform for drug target screening is likely
to advanceourunderstandingof stemcell biologyandaccelerate ap-
plications of stem cells to basic research. The path toward cell-
based therapies and the treatment of intractable diseases will
be significantly accelerated, once the research community
and clinicians possess sufficient numbers of well-defined and
plentiful immunophenotyping tools for stem cells and their
progeny.
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